Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Protalix Biotherapeutics Inc
PLXCurrent price
1.24 USD
-0.04 USD (-3.13%)
Last closed
1.32 USD
Company
www.protalix.com
ISIN
US74365A3095
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
Capitalization
85 309 536 USD
Yield for 12 month
-9.49 %
1Y
3Y
5Y
10Y
15Y
PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. Address: Science Park, Karmiel, Israel, 2161401
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12 USDP/E ratio
–Dividend Yield
–Current Year
+65 494 000 USD
Last Year
+47 638 000 USD
Current Quarter
+13 474 000 USD
Last Quarter
+3 748 000 USD
Current Year
+42 512 000 USD
Last Year
+28 046 000 USD
Current Quarter
+4 018 000 USD
Last Quarter
+1 146 000 USD
Key Figures PLX
1 year
3 years
5 years
10 years
EBITDA
-13 526 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-10.27 %
PEG Ratio
-0.1
Return On Equity TTM
-43.49 %
Wall Street Target Price
12 USD
Revenue TTM
38 053 000 USD
Book Value
0.39 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-61.6 %
Dividend Yield
–
Gross Profit TTM
28 046 000 USD
Earnings per share
-0.23 USD
Diluted Eps TTM
-0.23 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-39.2 %
Profit Margin
-38.62 %
Dividend Analytics PLX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
20.12.2019
Dividend Date
20.12.2019
Stock Valuation PLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1.8709
Enterprise Value Revenue
1.7458
Price Sales TTM
2.2419
Enterprise Value EBITDA
5.6271
Price Book MRQ
2.9848
Financials PLX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PLX
For 52 weeks
0.82 USD
1.9 USD
50 Day MA
1.08 USD
Shares Short Prior Month
3 271 953
200 Day MA
1.19 USD
Short Ratio
24.16
Shares Short
3 096 973
Short Percent
4.4 %
BeatStart